SCHEMBL1663806

SCHEMBL1663806

C[C]c1cccc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
CYP2A6 P11509 4/20 0.48
CHAT P28329 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
HSD17B10 Q99714 4/20 0.46
TSHR P16473 3/20 0.46
TDP1 Q9NUW8 2/20 0.46
GRM5 P41594 1/20 0.43
CYP1A2 P05177 6/20 0.42
CYP3A4 P08684 2/20 0.42
HPGD P15428 2/20 0.42
KEAP1 Q14145 1/20 0.42
HPRT1 P00492 1/20 0.42
CYP1B1 Q16678 2/20 0.39
CYP1A1 P04798 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
ABCB11 O95342 1/20 0.39
NR3C1 P04150 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1611988 0.81 CHAT (0.53) ALDH1A1CYP2A6CHATCA1CA2
SCHEMBL814962 0.79 HPRT1 (0.52) ALDH1A1CYP2A6CHATCA1CA2
SCHEMBL1141298 0.79 HPRT1 (0.52) ALDH1A1CYP2A6CHATCA1CA2
SCHEMBL29661843 0.79 CHAT (0.60) ALDH1A1CYP2A6CHATCA1CA2
SCHEMBL2776015 0.79 CHAT (0.60) ALDH1A1CYP2A6CHATCA1CA2
SCHEMBL10804459 0.79 HPRT1 (0.52) ALDH1A1CYP2A6CHATCA1CA2
SCHEMBL6364668 0.77 CHAT (0.58) ALDH1A1CYP2A6CHATCA1CA2
SCHEMBL28113790 0.76 CA1 (0.44) ALDH1A1CYP2A6CHATCA1CA2
SCHEMBL5865111 0.75 CA1 (0.47) ALDH1A1CYP2A6CHATCA1CA2
SCHEMBL507946 0.75 CA1 (0.47) ALDH1A1CYP2A6CHATCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5393760-A Cardiovascular disorders, antitumor agents HOFFMANN-LA ROCHE INC. (US) 1995-02-28 US claimed
EP-0468231-B1 Guanidins HOFFMANN LA ROCHE (CH) 1994-09-21 EP claimed
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-01 US disclosed
EP-2565210-B1 RESIN FINE POWDER CONSISTING OF 4-METHYL-1-PENTENE POLYMER, COMPOSITION CONTAINING SAME, AND PROCESS FOR PRODUCTION THEREOF MITSUI CHEMICALS INC (JP) 2019-11-06 EP disclosed
US-10457786-B2 Biaxially-stretched film and ethylene polymer composition PRIME POLYMER CO., LTD. (JP) 2019-10-29 US disclosed
US-20190177271-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2019-06-13 US disclosed
US-9902847-B2 4-methyl-1-pentene (co)polymer composition, and film and hollow molded product composed of the composition MITSUI CHEMICALS, INC. (JP) 2018-02-27 US disclosed
EP-2960270-B1 BIAXIALLY STRETCHED FILM, AND ETHYLENE-TYPE POLYMER COMPOSITION PRIME POLYMER CO LTD (JP) 2017-12-20 EP disclosed
EP-2799486-B1 ETHYLENE-BASED POLYMER COMPOSITION, AND MOLDED BODY OBTAINED FROM SAME MITSUI CHEMICALS INC (JP) 2017-08-23 EP disclosed
US-9657117-B2 4-methyl-1-pentene polymer, resin composition containing 4-methyl-1-pentene polymer, masterbatch thereof, and formed product thereof MITSUI CHEMICALS, INC. (JP) 2017-05-23 US disclosed
EP-2799488-B1 4-METHYL-1-PENTENE (CO)POLYMER COMPOSITION, AND FILM AND HOLLOW MOLDED BODY, EACH OF WHICH IS FORMED FROM 4-METHYL-1-PENTENE (CO)POLYMER COMPOSITION MITSUI CHEMICALS INC (JP) 2016-07-20 EP disclosed
EP-1302508-A1 AUTOMOTIVE PART MADE OF POLYPROPYLENE RESIN COMPOSITION Mitsui Chemicals, Inc. (JP) 2003-04-16 EP disclosed
EP-1138687-A1 METALLOCENE COMPOUND, PROCESS FOR PRODUCING METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST, PROCESS FOR PRODUCING POLYOLEFIN, AND POLYOLEFIN Mitsui Chemicals, Inc. (JP) 2001-10-04 EP disclosed
US-5763436-A ANTICOAGULANTS HOFFMANN-LA ROCHE INC. (US) 1998-06-09 US disclosed
US-5595999-A ANTICOAGULANTS HOFFMANN-LA ROCHE INC. (US) 1997-01-21 US disclosed
US-5583133-A ANTICOAGULANTS HOFFMANN-LA ROCHE INC. (US) 1996-12-10 US disclosed
US-5532232-A INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD HOFFMANN-LA ROCHE INC. (US) 1996-07-02 US disclosed
US-5393760-A Cardiovascular disorders, antitumor agents HOFFMANN-LA ROCHE INC. (US) 1995-02-28 US disclosed
US-5260307-A Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma HOFMANN-LA ROCHE INC. (US) 1993-11-09 US disclosed
US-4735959-A HYPOGLYCEMIC AGENTS DR. KARL THOMAE GMBH (DE) 1988-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190177271-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC ALDH1A1 1793/4885CYP2A6 2957/4885CHAT 3807/4885
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC ALDH1A1 1793/4885CYP2A6 2957/4885CHAT 3807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.